Prevoo MLL, Van ’T Hof MA, Kuper HHH, Van Leeuwen MA, Van De Putte LBA, Van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
Article
CAS
PubMed
Google Scholar
Fransen J, Van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23:S93–9.
CAS
PubMed
Google Scholar
Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
Article
PubMed
Google Scholar
Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. Rheumatology. 2010;49:1197–9.
Article
PubMed
Google Scholar
National Institute for Health and Care Excellence (Health Technology Appraisal). Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130), October 2007.
National Institute for Health and Care Excellence (guidelines in development). Final appraisal determination: Rheumatoid arthritis: adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept (ID537), August 2015
Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.
Article
PubMed
PubMed Central
Google Scholar
Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective: Evidence from the EuroQol BIO MED Research Programme. Rotterdam: Kluwer Academic Publishers; 2003.
Book
Google Scholar
Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. CARDERA Trial. Ann Rheum Dis. 2008;67(5):656–63.
Article
CAS
PubMed
Google Scholar
Scott DL, Ibrahim F, Farewell V, O’Keeffe AG, Ma M, Walker D, et al. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. Health Technol Assess. 2014;18(66):1–164.
Article
PubMed
PubMed Central
Google Scholar
Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol. 1993;20:557–60.
CAS
PubMed
Google Scholar
Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–32.
Article
PubMed
Google Scholar
Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev-Petersen K, Luukkainen RK, et al. Questionnaires in Standard Monitoring of Patients With Rheumatoid Arthritis Group. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008;58:2642–51.
Article
PubMed
Google Scholar
Jerram S, Butt S, Gadsby K, Deighton C. Discrepancies between the EULAR response criteria and the NICE guidelines for continuation of anti-TNF therapy in RA: a cause for concern? Rheumatology. 2008;47:180–2.
Article
CAS
PubMed
Google Scholar
van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39:34–40.
Article
PubMed
Google Scholar
Gülfe A, Geborek P, Saxne T. Response criteria for rheumatoid arthritis in clinical practice: how useful are they? Ann Rheum Dis. 2005;64:1186–9.
Article
PubMed
PubMed Central
Google Scholar
Gülfe A, Aletaha D, Saxne T, Geborek P. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. BMC Musculoskelet Disord. 2009;10:41.
Article
PubMed
PubMed Central
Google Scholar
Ward MM, Guthrie LC, Alba MI. Rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients? Arthritis Rheum. 2014;66:2339–43.
Article
Google Scholar
Ward MM, Guthrie LC, Alba MI. Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis. 2015;74:1691–6.
Article
PubMed
Google Scholar
Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-208324.
Kievit W, Fransen J, Adang EM, Kuper HH, Jansen TL, De Gendt CM, et al. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies. Ann Rheum Dis. 2009;68:844–9.
Article
CAS
PubMed
Google Scholar
Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Hetland ML. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol. 2010;37:285–90.
Article
PubMed
Google Scholar
Klarenbeek NB, Koevoets R, van der Heijde DM, Gerards AH, Ten Wolde S, Kerstens PJ, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011;70:1815–21.
Article
CAS
PubMed
Google Scholar
Alemao E, Samuel Joo S, Kawabata H, Al MJ, Allison PD, Rutten-Van Mölken MP, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME. Effects of achieving target measures in ra on functional status, quality of life and resource utilization: analysis of clinical practice data. Arthritis Care Res. 2016;68(3):308–17. doi:10.1002/acr.22678.
Article
CAS
Google Scholar
Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353:1568–73.
Article
PubMed
Google Scholar
Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52:36–41.
Article
PubMed
Google Scholar